Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study

Journal of the Formosan Medical Association - Tập 122 - Trang 1042-1049 - 2023
Yen-Ling Peng1, Chung-Hsin Chang2,3, Shu-Chen Wei2,4, Tien-Yu Huang2,5,6, Wei-Chen Tai2,5,7, Wen-Hung Hsu2,5,8,9, Deng-Chyang Wu2,5,8,9, Hsu-Heng Yen2,5,10, Chi-Ming Tai2,5,11, Chen-Wang Chang2,5,12,13, Wei-Chen Lin2,5,13, Horng-Yuan Wang2,5,12,13, Chun-Chi Lin2,14, Chia-Jung Kuo2,5,15, Cheng-Tang Chiu2,5,15, Ching-Pin Lin2,5,16, Hsi-Chang Lee2,5,17, Jia-Feng Wu2,18, Chen-Shuan Chung1,2,5,19
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
2Taiwan Society of Inflammatory Bowel Disease (TSIBD), Taipei, Taiwan
3Division of Gastroenterology and Hepatology, Department of Internal Medicine, IBD Center, Taichung Veterans General Hospital, Taichung City, Taiwan
4Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
5Taiwan Association for the Study of Small Intestinal Diseases (TASSID), New Taipei City, Taiwan
6Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
8Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan
9Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
10Division of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan
11Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan
12Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
13Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan
14Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
15Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
16Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan
17Division of Gastroenterology and Hepatology, Department of Internal Medicine, Renai Branch, Taipei City Hospital, Taipei, Taiwan
18Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
19College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

Tài liệu tham khảo

2022

Yen, 2019, Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study, Int Res, 17, 54

El Ouali, 2021, Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic, Curr Opin Gastroenterol, 37, 313, 10.1097/MOG.0000000000000741

Singh, 2021, vol. 9, 159

Nishida, 2021, Impact of the lockdown due to the COVID-19 pandemic on patients with inflammatory bowel disease, Front Med, 8, 649759, 10.3389/fmed.2021.649759

Łodyga, 2021, Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2, Pol Arch Intern Med, 131, 226

Papa, 2020, Epidemiology and the impact of therapies on the outcome of COVID-19 in patients with inflammatory bowel disease, Am J Gastroenterol, 115, 1722, 10.14309/ajg.0000000000000830

Segal, 2021, Implications of recurrent SARS-CoV-2 outbreaks for IBD management, Frontline Gastroenterol, 12, 316, 10.1136/flgastro-2020-101531

Barnes, 2021, Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic, JGH Open, 5, 585, 10.1002/jgh3.12537

Mahmud, 2021, Risk of venous thromboembolism among patients with inflammatory bowel disease who contract severe acute respiratory syndrome coronavirus 2, Gastroenterology, 161, 1709, 10.1053/j.gastro.2021.06.012

Walldorf, 2021, SARS-CoV-2 vaccination in patients with inflammatory bowel disease-fear and desire, Inflamm Bowel Dis, 27, 1858, 10.1093/ibd/izab150

Lee, 2022, Perceptions and behaviors of patients with inflammatory bowel disease during the COVID-19 crisis, Gut Liver, 16, 81, 10.5009/gnl210064

Bossa, 2021, Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs, Dig Liver Dis, 53, 277, 10.1016/j.dld.2020.12.120

Chebli, 2021, How to manage inflammatory bowel disease during the COVID-19 pandemic: a guide for the practicing clinician, World J Gastroenterol, 27, 1022, 10.3748/wjg.v27.i11.1022

Mak, 2021, Zero COVID-19 infection in inflammatory bowel disease patients: findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan, J Gastroenterol Hepatol, 36, 171, 10.1111/jgh.15164

2022, Monthly number of cases within the past 5 Years, severe pneumonia with novel pathogens (COVID-19), indigenous and imported, Nationwide, 2022

Scucchi, 2021, Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease, Eur Rev Med Pharmacol Sci, 25, 2418

Ungaro, 2022, Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of more than 6000 patients from an international registry, Gastroenterology, 162, 316, 10.1053/j.gastro.2021.09.011

Annapureddy, 2020, Biologics in systemic autoimmune diseases during, COVID-19 pandemic, 39, 3529

Bezzio, 2020, Biologic therapies may reduce the risk of COVID-19 in patients with inflammatory bowel disease, Inflamm Bowel Dis, 26, e107, 10.1093/ibd/izaa242

Richter, 2022, Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience, Eur J Gastroenterol Hepatol, 34, 267, 10.1097/MEG.0000000000002239

Kim, 2022, Management of inflammatory bowel disease in the COVID-19 era, Int Res, 20, 3

Khan, 2020, Adherence of infusible biologics during the time of COVID-19 among patients with inflammatory bowel disease: a nationwide veterans affairs cohort study, Gastroenterology, 159, 1592, 10.1053/j.gastro.2020.06.044

Refaie, 2022, Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease, Gastroenterol Hepatol, 45, 114, 10.1016/j.gastrohep.2021.03.012

Lewin, 2020, International organization for the study of inflammatory bowel disease: global strategies for telemedicine and inflammatory bowel diseases, Journal of Crohn’s and Colitis, 14, S780, 10.1093/ecco-jcc/jjaa140

Perisetti, 2021, Successful distancing: telemedicine in gastroenterology and Hepatology during the COVID-19 pandemic, Dig Dis Sci, 66, 945, 10.1007/s10620-021-06874-x

Costantino, 2021, Trust in telemedicine from IBD outpatients during the COVID-19 pandemic, Dig Liver Dis, 53, 291, 10.1016/j.dld.2020.10.035

Fiorino, 2020, Clinician education and adoption of preventive measures for COVID-19: a survey of a convenience sample of general practitioners in Lombardy, Italy, Ann Intern Med, 173, 405, 10.7326/M20-1447

Siegel, 2021, SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting, Gut, 70, 635, 10.1136/gutjnl-2020-324000

Botwin, 2021

2022, Our world in data, Coronavirus Pandemic

Spadaccini, 2021, What gastroenterologists should know about SARS-CoV 2 vaccine: world Endoscopy Organization perspective, United European Gastroenterol, 9, 787, 10.1002/ueg2.12103

Hadi, 2021, COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: analysis of a Large multi-institutional research network in the United States, Gastroenterology, 161, 1336, 10.1053/j.gastro.2021.06.014

Thông tin
Thông tin xuất bản

Journal of the Formosan Medical Association

Tập 122

1042-1049

Thông tin tác giả